Arch Biopartners Fast-Tracks Novel Therapy for Diabetic Kidney Disease

TORONTO, ON – July 17, 2026 – In a significant move to combat one of the world's most pervasive chronic illnesses, therapeutic biotechnology firm Arch Biopartners announced today it has engaged a specialized U.S. bioengineering laboratory to accelerate its chronic kidney disease (CKD) program. The collaboration aims to fast-track the development of a novel drug candidate targeting interleukin-32 (IL-32), a key inflammatory protein implicated in diabetic kidney disease (DKD), a condition that remains a leading cause of kidney failure globally.

This strategic R&D push, designed to move the company’s promising asset toward human clinical trials, was announced alongside a corporate update confirming its ongoing market-making agreement with Red Cloud Securities Inc. The dual announcements paint a picture of a company aggressively building fundamental asset value in the lab while simultaneously working to ensure market stability, a crucial combination for any clinical-stage biotech navigating the long road to commercialization.

A Targeted Strike Against a Silent Epidemic

Chronic kidney disease is a silent, progressive condition affecting over 800 million people worldwide. For the estimated 40% of patients whose disease is driven by diabetes, the prognosis can be grim. Diabetic kidney disease is not just a complication; it is the single largest cause of kidney failure in the United States, forcing countless individuals into life-altering dialysis or a desperate wait for a transplant. Despite its prevalence, the therapeutic landscape has been starved for innovation, with most current treatments managing symptoms or related conditions like high blood pressure, rather than directly halting the disease's destructive march.

Arch Biopartners aims to change this paradigm by taking a direct, on-target approach. The company's program, which it acquired in late 2025 through the purchase of Lipdro Therapeutics, is built on compelling evidence that IL-32 is a central actor in the pathology of DKD. Peer-reviewed research published in Inflammation Research earlier this year provided further validation, linking IL-32 to the metabolic stress, chronic inflammation, and tubular injury that characterize the disease's progression in the kidneys. By developing a therapy to inhibit IL-32, Arch is attempting to neutralize a key driver of the disease at its source.

The new partnership with the U.S. laboratory is a critical step in translating this scientific theory into a tangible therapy. The program is currently in the pre-Investigational New Drug (pre-IND) stage—a crucial phase of development where a company gathers the necessary safety and efficacy data required by regulators before a potential drug can be tested in humans.

“This research contract is an important step in advancing the Company’s IL-32 CKD drug development program,” said Richard Muruve, Chief Executive Officer of Arch Biopartners. “This work will help move the program forward while building a proprietary body of data to support the Company’s development and partnering strategy.”

The Strategic Partnership and Intellectual Property Play

While the name of the U.S.-based bioengineering lab remains undisclosed, Arch has stated it was selected for its specific core competencies in the field. This collaboration is about more than just accelerating timelines; it's a strategic move to build a fortress of proprietary data around the IL-32 asset. In the high-stakes world of biopharmaceutical development, a robust patent portfolio and a deep well of unique data are the currency of value.

By generating this data, Arch not only strengthens its future IND application to regulatory bodies but also significantly enhances the asset's value for potential licensing or partnership deals with larger pharmaceutical companies. This de-risking process is fundamental to the biotech business model, where smaller, innovative firms often pioneer novel mechanisms before joining forces with established players who have the resources for large-scale Phase III trials and global commercialization. This move demonstrates a clear-eyed focus on the long-term return on investment, aligning scientific progress with a sound corporate development strategy.

This initiative is the logical next step in a strategy that began with the acquisition of the IL-32 platform in September 2025. By methodically advancing the program from acquisition to focused, outsourced development, Arch is demonstrating a disciplined approach to building out its pipeline and tackling a market with a profound unmet need.

Beyond the Science: Fortifying Market Position

In parallel with its scientific advancements, Arch Biopartners is also tending to its financial health and market presence. The company’s update on its market-making agreement with Red Cloud Securities Inc. (RCSI) may seem like a minor corporate footnote, but it offers insight into the practical realities of funding innovation. For a publicly-traded junior biotech on the TSX Venture Exchange, maintaining a stable and liquid market for its shares is paramount.

Market makers like RCSI are engaged to facilitate trading, reduce the spread between bid and ask prices, and ultimately ensure an orderly market. This can help mitigate volatility and improve investor confidence, which is critical for a company that relies on the capital markets to fund its multi-year, multi-million-dollar research programs. The agreement, under which Arch pays a standard C$5,000 monthly fee, is a common and transparent tool used to support a healthy trading environment. By ensuring RCSI continues this role, Arch is actively managing its interface with the investment community, signaling stability as it pursues its long-term R&D goals.

A Diversified Pipeline Targeting Kidney Health

The new IL-32 program does not exist in a vacuum. It represents a strategic expansion for Arch Biopartners, adding a chronic disease focus to a pipeline already centered on protecting the kidneys from acute injury (AKI). The company is concurrently advancing two other drug candidates in Phase II clinical trials, both of which target the DPEP-1 pathway, a key mediator of inflammation.

Its lead asset, LSALT peptide (Metablok), is being evaluated to prevent cardiac surgery-associated AKI, a common and dangerous complication of open-heart procedures. Patient enrollment for this trial began in April 2026, with the first patient dosed in May, indicating tangible progress. The company’s second clinical-stage asset, a repurposed drug named Cilastatin, is being tested for its ability to prevent AKI induced by toxins, such as those from radiographic contrast dyes used in medical imaging.

Together, these three programs form a comprehensive and integrated approach to kidney health. By targeting distinct but related causes of kidney damage—acute inflammation, toxins, and the chronic inflammatory processes of DKD—Arch is building a focused franchise with deep expertise in renal disease. This multi-pronged strategy diversifies risk and creates multiple opportunities for clinical success, positioning the company as a dedicated innovator in a field desperate for new solutions.